We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. Journal of Experimental Medicine, 2023; 220 (7) DOI: 10.1084/jem.20221654 ...

Though these pieces of viral RNA and protein were non-functional "debris," the researchers found that they were enough to stimulate an immune response. Since stronger HIV-specific immune responses ...

Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their ...

Scientists have determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, or the process through which the virus propagates itself and ...

Using something called an HIV-like particle (HLP)—which are dead HIV particles containing HIV proteins that trigger an immune response in a patient—may help treat the disease, scientists from ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Women living with HIV represent 23% of people affected in Canada and form the second fastest-growing group, after Indigenous people. However, women are systematically underrepresented in HIV trials.

The in vitro experiments found that introducing the Nef protein to immune cells resulted in the expression of pro-inflammatory genes that remain switched on, even when the HIV protein was no ...

Medical advancements are a wonderful thing. When HIV was first discovered back in the 1980s, it was considered a death ...

HIV anti-retroviral therapy is considered a treatment and not a cure because patients usually carry a reservoir of HIV-infected cells that can re-emerge if treatment stops. These reservoirs have ...